PROCEPT BioRobotics appoints Dr. Michael Mack to board, increasing size from nine to ten directors

PROCEPT BioRobotics Corp

The board approved increasing its size from nine to ten members and appointed Dr. Michael Mack as a Class II director, effective October 2, 2026.
Dr. Mack is an independent director, and his initial term will expire at the company's 2029 annual meeting of stockholders.
Mack is a cardiac surgeon in Dallas since 1982 who is board-certified in internal medicine, general surgery and thoracic surgery and has more than 1,100 peer-reviewed publications.
He will be compensated consistent with other non-employee directors and will enter the company's standard director and officer indemnification and advancement agreement.
No arrangements or understandings with other persons and no related-party transactions involving Dr. Mack were disclosed.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.